 ROCKVILLE, MD, Nov. 09, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Companys management will participate in the following investor conferences in November and December: 